The Prominence of the Broad-Spectrum Protease inhibitor gene A2ML1 as a potential biomarker in cervical cancer diagnostics using Immunotherapeutic and Multi-Omics approaches
-
Published:2024-12
Issue:
Volume:142
Page:113126
-
ISSN:1567-5769
-
Container-title:International Immunopharmacology
-
language:en
-
Short-container-title:International Immunopharmacology
Author:
Naveed Muhammad, Saad Mughal Muhammad, Aziz TariqORCID, Jabeen Khizra, Ali Khan Ayaz, Alhomrani Majid, Alsanie Walaa F., Alamri Abdulhakeem S.
Reference33 articles.
1. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials;Monk;Cancer Treat Rev.,2022 2. Predictors of cervical cancer being at an advanced stage at diagnosis in Sudan;Ibrahim;Int J Womens Health.,2011 3. Reza MS, Harun-Or-Roshid M, Islam MA, Hossen MA, Hossain MT, Feng S, Xi W, Mollah MNH, Wei Y. Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for Cervical Cancer. Int J Mol Sci. 2022, 2,23(7):3968. 4. van Luijk IF, Smith SM, Marte Ojeda MC, Oei AL, Kenter GG, Jordanova ES. A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment. J Clin Med, 2022, 19;11(9):2277. 5. Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, Guo AY. ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy. Adv Sci (Weinh). 2020, 11;7(7):1902880.
|
|